Name: Wegovy Korean Version
Price: 448 USD
Rating: 4.7 (336 reviews)

Wegovy Korean Version

$448.00

Wegovy Korean Version is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Clinical data demonstrate 15% mean weight reduction (35 lb from baseline) over 68 weeks, with 86% of patients achieving ≥5% weight loss through hypothalamic appetite regulation and delayed gastric emptying. This once-weekly injectable requires medical supervision and follows a structured 5-step titration protocol.

Out of stock

Wegovy® Korean Version

FDA-Approved GLP-1 Receptor Agonist for Chronic Weight Management

Product Overview

Wegovy^® (semaglutide) is an FDA-approved GLP-1 receptor agonist indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. In 68-week clinical trials, 86% of patients achieved ≥5% weight loss, with a mean 15% weight reduction (average loss of 35 lbs from 232 lb baseline). Wegovy works by regulating hypothalamic appetite signals and delaying gastric emptying for sustained caloric control.

Key Benefits

Clinically Significant Weight Loss

3x greater weight loss vs placebo in phase III trial (N=1,961)

Cardiometabolic Benefits

Improves blood pressure, LDL cholesterol, and HbA1c levels

Titration Protocol

5-step dose escalation over 20 weeks to minimize GI side effects

Sustainable Results

2-year extension trials show sustained 15% weight loss

Mechanism of Action

GLP-1 Analog Technology

Binds to GLP-1 receptors in the pancreas and CNS
Enhances satiety signals and reduces hunger perception
Delays gastric emptying to promote fullness
94% bioavailability via subcutaneous injection

Packaging Specifications

Formulation: Prefilled injection pen (semaglutide)
Storage: Refrigerate at 2–8°C. Do not freeze.
Administration: Single-use prefilled pen. Discard after use.
Dosages: Customized prefilled pens with progressive strengths

Clinical Administration Protocol

Frequency

Once weekly, any time of day

Injection Sites

Abdomen, thigh, or upper arm

Dose Adjustment

Mandatory 4-week titration period

Titration Schedule

Month 1: 0.25 mg once weekly
Month 2: 0.5 mg once weekly
Month 3: 1 mg once weekly
Month 4: 1.7 mg once weekly
Month 5+: Maintenance dose of 2.4 mg once weekly

IMPORTANT SAFETY INFORMATION AND DISCLAIMER

Contraindications: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Potential Risks: Monitor patients for pancreatitis and gallbladder-related adverse events
Healthcare Supervision: Requires prescription by and supervision of a licensed healthcare provider
Individual Results May Vary: Clinical outcomes depend on patient adherence, lifestyle modifications, and biological factors

This product is available only through licensed healthcare providers. Novo Nordisk assumes no liability for unsupervised use. Consultation with a healthcare professional is required prior to initiation of therapy to review risks, benefits, and appropriate patient selection.

Wegovy Korean Version

Wegovy® Korean Version

Reviews

Dr. Lipo+ Prime

Dr.Lipo+(Body)

Kabelline Contouring Serum

Lipo Lab PPC Solution

Lipo Lab V-line Premium

Lipo Vela 10ml*10

Pine Bottle

Slim point-Body

Popular Categories

Useful Links

4,5

/5

Wegovy Korean Version

Wegovy® Korean Version

Reviews

Related products

Popular Categories

Useful Links

4,5

/5